Study guide
8.2 Advanced & Metastatic Breast Cancer Targeted Strategies
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
8.2 Advanced & Metastatic Breast Cancer Targeted Strategies
Key Takeaways Explain This Topic AI
First-line treatment for HR+/HER2- metastatic breast cancer is a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) combined with an aromatase inhibitor or fulvestrant; ribociclib is distinguished by statistically significant overall survival benefits exceeding 12 months across multiple Phase 3 trials (MONALEESA-2, -3, -7).
Second-line therapy for HR+/HER2- metastatic breast cancer post-CDK4/6 progression is strictly biomarker-guided: elacestrant for acquired ESR1 mutations (EMERALD trial), alpelisib + fulvestrant for PIK3CA mutations (SOLAR-1), capivasertib + fulvestrant for AKT1/PIK3CA/PTEN alterations (CAPItello-291), or PARP inhibitors (olaparib, talazoparib) for germline BRCA mutations.
Trastuzumab deruxtecan (T-DXd) has fundamentally transformed HER2-targeted oncology, demonstrating unprecedented PFS and OS superiority over T-DM1 in second-line HER2+ metastatic breast cancer (DESTINY-Breast03) and establishing the 'HER2-Low' paradigm (IHC 1+ or IHC 2+/ISH-) in pretreated metastatic disease (DESTINY-Breast04).
Active or untreated HER2-positive brain metastases are preferentially managed with the CNS-penetrant tucatinib + trastuzumab + capecitabine regimen (HER2CLIMB trial), which confers significant intracranial and overall survival advantages.
Sacituzumab govitecan (anti-Trop-2 ADC with SN-38 payload) significantly improves PFS and OS in pretreated metastatic triple-negative breast cancer (ASCENT) and HR+/HER2- disease (TROPiCS-02); pharmacists must manage boxed warnings for severe neutropenia and diarrhea, recognizing that homozygous UGT1A1*28 patients have heightened toxicity risk.
Last updated: August 2026
8.2 Advanced & Metastatic Breast Cancer Targeted Strategies
Metastatic Breast Cancer (mBC; Stage IV) remains an incurable malignancy with a median overall survival ranging from ~12–18 months in triple-negative disease to >5 years in HER2-positive and indolent HR-positive disease. The overarching therapeutic goals in the metastatic setting are prolonging overall survival (OS) , delaying disease progression , controlling cancer-related symptoms , and preserving health-related quality of life (QoL) .
Modern precision therapeutics in mBC rely heavily on serial tissue or liquid (ctDNA) biomarker profiling, antibody-drug conjugate (ADC) engineering, and targeted small-molecule pathway inhibition.
- 1. HR+/HER2- Metastatic Breast Cancer: Frontline & Resistance Strategies
- Frontline Standard: CDK4/6 Inhibitors + Endocrine Therapy
The combination of a Cyclin-Dependent Kinase 4/6 ( CDK4/6 ) inhibitor ( palbociclib, ribociclib, abemaciclib ) plus an Aromatase Inhibitor (letrozole or anastrozole) or Fulvestrant is the undisputed standard of care for frontline HR+/HER2- metastatic breast cancer. +-----------------------------------------------------------------------------+
- | CDK4/6 INHIBITOR CLINICAL EFFICACY MATRIX |
- | |
- | [RIBOCICLIB (MONALEESA Trials)] |
- | - MONALEESA-2 (Postmenopausal frontline + Letrozole): Median OS 63.9 vs |
- | 51.4 months (HR 0.76, p = 0.008) -> +12.5 MONTH OS BENEFIT! |
- | - MONALEESA-3 (Frontline/2nd-line + Fulvestrant): OS HR 0.72 (p = 0.00455)|
- | - MONALEESA-7 (Premenopausal + OFS + ET): OS HR 0.71 (p = 0.0097) |
- | - Consistent, statistically significant OS advantage across all settings! |
- | |
- | [ABEMACICLIB (MONARCH Trials)] |
- | - MONARCH-2 (Second-line + Fulvestrant): Median OS 46.7 vs 37.3 months |
- | (HR 0.757, p = 0.01) -> +9.4 MONTH OS BENEFIT! |
- | - MONARCH-3 (Frontline + AI): Significant PFS prolongation (29.0 vs 14.8m)|
- | |
- | [PALBOCICLIB (PALOMA Trials)] |
- | - PALOMA-2 (Frontline + Letrozole) & PALOMA-3 (Second-line + Fulvestrant):|
- | Doubled PFS (~25 vs 14 months); OS trended positive but failed to reach |
- | statistical significance in ITT population. |
- +-----------------------------------------------------------------------------+
- Second-Line Biomarker-Driven Therapy Post-CDK4/6 Progression
Upon disease progression on frontline CDK4/6 inhibitor therapy, repeat genomic profiling via circulating tumor DNA (ctDNA liquid biopsy) or metastatic tissue biopsy is mandatory to identify actionable resistance mutations: +-----------------------------------------------------------------------------+
- | BIOMARKER-DRIVEN SECOND-LINE ALGORITHM IN HR+/HER2- mBC |
- | |
- | PROGRESSION ON FRONTLINE CDK4/6 INHIBITOR + ENDOCRINE THERAPY |
- | | |
- | Perform ctDNA / NGS Genomic Testing |
- | | |
- | +---------------+---------------+---------------+---------------------+ |
- | | | | | | |
- | v v v v v |
- | [ESR1 MUTATION] [PIK3CA MUT] [AKT1/PTEN/PIK] [gBRCA MUTATION] [NO MUTATION]|
- | (Y537S, D538G) (E542K, H1047R) (Alterations) (BRCA1 / BRCA2) (Wild-Type) |
- | | | | | | |
- | v (EMERALD) v (SOLAR-1) v (CAPItello) v (OlympiAD/EMBRACA) v |
- | [ELACESTRANT] [ALPELISIB] [CAPIVASERTIB] [PARP INHIBITOR] [EVEROLIMUS]|
- | 345 mg PO Daily + Fulvestrant + Fulvestrant Olaparib / Talazo + Exemestane|
- | Oral SERD 300 mg PO Daily 400 mg PO BID Synthetic Lethal SWISH Rinse |
- | Take with food Metformin Proph 4-on / 3-off PARP Trapping (BOLERO-2) |
- +-----------------------------------------------------------------------------+
- Detailed Second-Line Targeted Agents in HR+/HER2- mBC
Elacestrant (EMERALD Trial): First-in-class oral Selective Estrogen Receptor Degrader (SERD) . ESR1 ligand-binding domain mutations (e.g., Y537S, D538G) confer ligand-independent constitutive estrogen receptor signaling, rendering aromatase inhibitors totally inactive. Elacestrant binds to the ER, induces receptor degradation, and halts transcription. In the EMERALD trial, elacestrant monotherapy (345 mg PO daily with food) achieved significant PFS prolongation over standard endocrine therapy in ESR1 -mutated tumors (PFS HR 0.55). Adverse effects: nausea (35%), musculoskeletal pain, hypercholesterolemia, dyspepsia.
Alpelisib (SOLAR-1 Trial): Alpha-specific phosphatidylinositol-3-kinase ( PI3K-alpha ) inhibitor. PIK3CA activating mutations occur in ~40% of HR+/HER2- mBC. Alpelisib (300 mg PO daily with food) combined with fulvestrant prolonged median PFS from 5.7 to 11.0 months (HR 0.65). Signature toxicities:
Hyperglycemia (65%, Grade 3/4 in 35%): PI3K-alpha mediates insulin signaling in muscle and liver. Require baseline Fasting Plasma Glucose (<140 mg/dL) and HbA1c (<6.5%). Initiate metformin at first sign of dysglycemia.
Cutaneous Rash (50%, Grade 3 in 20%): Prophylactic oral antihistamines ( cetirizine 10 mg daily ) during the first 8 weeks reduce Grade >=2 rash from 60% to 26%.
Capivasertib (CAPItello-291 Trial): Potent, selective pan- AKT inhibitor (AKT1, AKT2, AKT3) . Approved in combination with fulvestrant for patients whose tumors harbor one or more alterations in PIK3CA , AKT1 , or PTEN (~50% of HR+ mBC). Dosing: 400 mg PO BID, taken 4 days on and 3 days off weekly with or without food. Intermittent dosing allows metabolic recovery. Primary toxicities: diarrhea (72%), cutaneous rash (38%), hyperglycemia (16%).
Everolimus (BOLERO-2 Trial): Oral mTORC1 inhibitor (10 mg PO daily) combined with exemestane (25 mg daily) doubles median PFS (7.8 vs 3.2 months, HR 0.45). Toxicity: Aphthous stomatitis (60%). Prophylactic dexamethasone 0.5 mg/5 mL oral swish-and-spit solution (10 mL QID for 8 weeks per SWISH trial) reduces Grade >=2 stomatitis from 33% to 2%.
2. HER2-Positive Metastatic Breast Cancer: Treatment Paradigms
Amplification or overexpression of the ERBB2 (HER2) oncogene occurs in ~15–20% of breast cancers. HER2 lacks a known natural ligand but readily homodimerizes or heterodimerizes with HER3, HER1 (EGFR), and HER4 to trigger intense downstream MAPK and PI3K survival signaling. +-----------------------------------------------------------------------------+
- | HER2+ METASTATIC LINE OF THERAPY ROADMAP |
- | |
- | [1ST-LINE STANDARD: CLEOPATRA REGIMEN] |
- | - Docetaxel (75 mg/m2) + Trastuzumab (8->6 mg/kg) + Pertuzumab (840->420mg)|
- | - Landmark Median Overall Survival: **57.1 MONTHS** (HR 0.68, p < 0.001) |
- | - Taxane discontinued after 6-8 cycles; HP maintained until progression |
- | | |
- | v |
- | [2ND-LINE GOLD STANDARD: DESTINY-Breast03] |
- | - **TRASTUZUMAB DERUXTECAN (T-DXd)**: 5.4 mg/kg IV Q3W |
- | - 12-month PFS: **75.8% vs. 34.1%** vs T-DM1 (PFS HR 0.28, p < 0.0001) |
- | - Superior OS over T-DM1 (HR 0.64); new undisputed second-line standard |
- | - Critical Surveillance: **Interstitial Lung Disease (ILD) / Pneumonitis**|
- | | |
- | v |
- | [3RD-LINE & BRAIN METASTASES: HER2CLIMB REGIMEN] |
- | - **TUCATINIB** (300 mg PO BID) + **TRASTUZUMAB** + **CAPECITABINE** |
- | - Active & treated CNS metastases: Intracranial PFS HR 0.32, OS HR 0.66 |
- | - Alternative 3rd/4th line: T-DM1 (EMILIA), Neratinib+Cap, Margetuximab |
- +-----------------------------------------------------------------------------+
- Master Comparison: HER2-Targeted Agents in Metastatic Disease
Drug / Regimen Target & Mechanism Landmark Clinical Trial Key Indications & Dosing Signature Toxicities & Pharmacist Interventions
Pertuzumab + Trastuzumab + Docetaxel (THP) Dual HER2 extracellular domain inhibition (Trastuzumab: Domain IV; Pertuzumab: Domain II dimerization arm) CLEOPATRA (Swain et al. Lancet Oncol 2015) Frontline HER2+ mBC.; Pertuzumab: 840 mg load, then 420 mg Q3W.; Trastuzumab: 8 mg/kg load, then 6 mg/kg Q3W. Diarrhea, alopecia, neutropenia, cardiotoxicity. LVEF monitoring Q3M. Fixed-dose SC formulation ( Phesgo : Pertuzumab 1200mg/Trastuzumab 600mg load, then 600mg/600mg SC Q3W) reduces infusion chair time.
Trastuzumab Deruxtecan (T-DXd) HER2-targeted ADC: Humanized IgG1 mAb linked to potent Topoisomerase I inhibitor ( Deruxtecan / DXd ) via cleavable tetrapeptide linker; DAR ~8:1 DESTINY-Breast03 (Cortés et al. NEJM 2022) Second-line HER2+ mBC post-trastuzumab/taxane.; Dose: 5.4 mg/kg IV Q3W . Boxed Warning for ILD/Pneumonitis (10–15%, fatal in 1–2%) and Neutropenia. High emetogenic potential (mandates 3-drug CINV prophylaxis: 5-HT3 RA + Dexamethasone + NK1 RA).
Tucatinib Selective small-molecule HER2 tyrosine kinase inhibitor (spares EGFR, minimizing wild-type skin/GI toxicities) HER2CLIMB (Murthy et al. NEJM 2020) Pretreated HER2+ mBC, including active/progressive brain metastases .; Dose: 300 mg PO BID (+ Trastuzumab + Capecitabine). Diarrhea (81%, manage with loperamide), elevated transaminases (ALT/AST), hyperbilirubinemia. Inhibits renal tubular transporters (OCT2/MATE1) causing benign SCr elevation. Strong CYP2C8 inhibitor.
Trastuzumab Emtansine (T-DM1) HER2-targeted ADC: Trastuzumab linked via non-cleavable thioether linker (MCC) to microtubule inhibitor DM1 (maytansinoid) ; DAR ~3.5:1 EMILIA (Verma et al. NEJM 2012) Pretreated HER2+ mBC (historical 2nd-line, now 3rd-line after T-DXd).; Dose: 3.6 mg/kg IV Q3W . Thrombocytopenia (30%) , Hepatotoxicity (elevated AST/ALT, nodular regenerative hyperplasia), peripheral neuropathy. Non-cleavable linker requires lysosomal degradation within target cell.
Margetuximab Fc-engineered anti-HER2 IgG1 monoclonal antibody with enhanced affinity for CD16A (activating Fc-gamma-RIIIa) and decreased affinity for CD16B (inhibitory Fc-gamma-RIIb) SOPHIA (Ruggero et al. JAMA Oncol 2021) Pretreated HER2+ mBC (+ Chemotherapy).; Dose: 15 mg/kg IV Q3W . Enhances Antibody-Dependent Cellular Cytotoxicity (ADCC). Greatest PFS advantage observed in patients carrying the CD16A-158F low-affinity allele . Infusion reactions, cardiotoxicity.
3. The HER2-Low Paradigm & Next-Generation ADCs
Historically, breast cancer was classified binarily as either HER2-positive (eligible for anti-HER2 therapies) or HER2-negative. The landmark DESTINY-Breast04 trial shattered this paradigm by proving the efficacy of Trastuzumab Deruxtecan (T-DXd) in HER2-Low Metastatic Breast Cancer : +-----------------------------------------------------------------------------+
- | THE HER2-LOW CLASSIFICATION |
- | |
- | - Definition: Immunohistochemistry (IHC) 1+ OR |
- | IHC 2+ with In Situ Hybridization (ISH) Non-Amplified |
- | - Prevalence: Comprises ~55-60% of all breast cancers (~65% of HR+ and |
- | ~35% of traditional triple-negative breast cancers). |
- | |
- | [DESTINY-Breast04 TRIAL: T-DXd 5.4 mg/kg IV Q3W] (Modi et al. NEJM 2022) |
- | - Population: HER2-low mBC previously treated with 1-2 lines of chemo. |
- | - HR+ Cohort: Median PFS **10.1 vs. 5.4 months** (HR 0.51, p < 0.0001) |
- | Median OS **23.9 vs. 17.5 months** (HR 0.64, p = 0.003) |
- | - Overall Cohort (including TNBC): PFS HR 0.50, OS HR 0.64 |
- +-----------------------------------------------------------------------------+
- Molecular Mechanics of the ADC "Bystander Antitumor Effect"
The revolutionary efficacy of T-DXd in HER2-low tumors relies on structural innovations over first-generation ADCs (like T-DM1): +-----------------------------------------------------------------------------+
- | ADC STRUCTURAL BIOLOGY & THE BYSTANDER EFFECT |
- | |
- | 1. HIGH DRUG-TO-ANTIBODY RATIO (DAR ~8:1): |
- | T-DXd carries 8 deruxtecan payload molecules per antibody (vs ~3.5 for |
- | T-DM1), maximizing cytotoxic payload delivery per receptor binding. |
- | |
- | 2. TUMOR-SELECTIVE CLEAVABLE LINKER: |
- | Tetrapeptide linker (GGFG) is stably intact in circulation but rapidly |
- | cleaved by lysosomal cathepsins upregulated inside tumor cells. |
- | |
- | 3. MEMBRANE-PERMEABLE CYTOTOXIC PAYLOAD (DXd): |
- | Unlike charged DM1, deruxtecan is lipophilic and membrane-permeable. |
- | Upon intracellular release and tumor cell kill, free DXd diffuses |
- | across the plasma membrane into adjacent tumor cells regardless of |
- | their HER2 expression -> THE BYSTANDER EFFECT kills heterogeneous, |
- | HER2-negative neighbor cells! |
+-----------------------------------------------------------------------------+ +-----------------------------------------------------------------------------+
- | PHARMACIST PROTOCOL: T-DXd INTERSTITIAL LUNG DISEASE (ILD) |
- | |
- | - Incidence: 10-15% of patients (median onset ~5-7 months). |
- | - Patient Education: Instruct patient to report any new/worsening cough, |
- | dyspnea, fever, or respiratory symptoms IMMEDIATELY. |
- | - Monitoring: Routine chest CT restaging scans reviewed for ground-glass |
- | opacities or reticular infiltrates. |
- | |
- | [GRADE 1 (Asymptomatic radiographic changes only)] |
- | - HOLD T-DXd immediately. |
- | - Consider systemic corticosteroids (e.g., prednisone >= 0.5 mg/kg/day). |
- | - If resolved completely within 28 days: May resume at next lower dose |
- | level (4.4 mg/kg). If resolution takes >28 days: Permanently discontinue|
- | |
- | [GRADE 2, 3, or 4 (Symptomatic ILD / Pneumonitis)] |
- | - **PERMANENTLY DISCONTINUE T-DXd IMMEDIATELY.** |
- | - Initiate prompt systemic corticosteroids: Prednisone >= 1 mg/kg/day |
- | (or equivalent IV methylprednisolone) with a slow taper over >=14 days. |
- +-----------------------------------------------------------------------------+
- 4. Metastatic Triple-Negative Breast Cancer (mTNBC)
Metastatic TNBC is characterized by aggressive clinical biology, lack of targeted hormonal options, and rapid development of chemotherapy resistance. Frontline systemic therapy is determined by PD-L1 expression and germline BRCA1/2 status . +-----------------------------------------------------------------------------+
- | FRONTLINE & SECOND-LINE mTNBC DECISION TREE |
- | |
- | METASTATIC TRIPLE-NEGATIVE BREAST CANCER DIAGNOSIS |
- | (Test: PD-L1 IHC 22C3 CPS, Germline BRCA1/2, Trop-2) |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v v |
- | [PD-L1 POSITIVE (CPS >= 10)] [PD-L1 NEGATIVE] |
- | (KEYNOTE-355: Cortes et al. NEJM 2022) | |
- | - **PEMBROLIZUMAB + CHEMOTHERAPY** v |
- | * Pembro 200 mg Q3W + Nab-paclitaxel (100 mg/m2) Check Germline BRCA |
- | * OR Pembro + Paclitaxel (80 mg/m2) | |
- | * OR Pembro + Gemcitabine/Carboplatin +----+----+ |
- | - Median OS: **23.0 vs. 16.1 months** (HR 0.73, p=0.009) | | |
- | v v |
- | (gBRCA+) (gBRCA-WT) |
- | [PARPi] [Chemo] |
- | Olaparib Plat/Taxane |
- | | Talazo |
- | v |
- | [SECOND-LINE & BEYOND: SACITUZUMAB GOVITECAN] (ASCENT: Bardia NEJM 2021) |
- | - Target: Trophoblast Cell-Surface Antigen 2 (**Trop-2**) (>90% of TNBC) |
- | - Payload: **SN-38** (Active topoisomerase I metabolite of irinotecan) |
- | - Hydrolyzable CL2A linker allows extracellular and intracellular release |
- | - Dose: **10 mg/kg IV on Days 1 and 8 of 21-day cycle** |
- | - Median PFS: **5.6 vs. 1.7 months** (HR 0.41, p < 0.001) |
- | - Median OS: **12.1 vs. 6.7 months** (HR 0.48, p < 0.001) |
- | - Also approved in HR+/HER2- mBC post-ET and >=2 chemos (TROPiCS-02) |
- +-----------------------------------------------------------------------------+
- Sacituzumab Govitecan Boxed Warnings & Clinical Management
Severe Neutropenia: Grade 3/4 neutropenia occurs in 51% of patients, with febrile neutropenia in 10%. Withhold therapy for ANC < 1,500/mcL on Day 1 or ANC < 1,000/mcL on Day 8. Secondary G-CSF prophylaxis (filgrastim or pegfilgrastim) is frequently required.
Severe Diarrhea: Occurs in 60% (Grade 3/4 in 10–14%). For acute cholinergic diarrhea during infusion, administer atropine 0.4–1 mg IV/SC . For delayed diarrhea, initiate high-dose loperamide (4 mg at first onset, then 2 mg every 2 hours until diarrhea-free for 12 hours) and aggressive oral hydration.
Pharmacogenomics (UGT1A1*28): SN-38 is cleared via hepatic glucuronidation by UDP-glucuronosyltransferase 1A1 (UGT1A1) . Patients homozygous for the UGT1A1*28 allele (7/7 genotype; Gilbert syndrome phenotype, present in ~10% of North Americans) experience impaired SN-38 clearance, resulting in elevated systemic SN-38 exposure and substantially higher risks of severe Grade 4 neutropenia, febrile neutropenia, and severe diarrhea. Clinical pharmacists must advocate for close hematologic surveillance and early dose reduction in UGT1A1*28/*28 patients.